Prabhudas Lilladher is bullish on Ipca Laboratories has recommended buy rating on the stock with a target price of Rs 1710 in ...

Ipca Laboratories Ltd (BOM:524494) reports robust domestic and export growth, with significant improvements in EBITDA margins despite challenges in certain segments.

Motilal Oswal is bullish on Ipca Laboratories recommended buy rating on the stock with a target price of Rs 1720 in its ...

Lupin, Biocon, Torrent Pharma and IPCA Labs -- Nuvama has assigned a ‘Buy’ rating on these four scrips. The triggers are ...

Nuvama has flagged four pharma stocks as top ‘Buy’ picks, citing strong US launches, biosimilars traction and margin ...

Ipca Laboratories reported a 31% rise in December quarter profit, supported by double-digit growth in Indian formulations and ...

When it comes to serious quality issues at India’s Ipca Laboratories, the FDA is letting bygones be bygones in its effort to get more promising but untested treatments for COVID-19 to the market. Ipca ...

BENGALURU, April 24 (Reuters) - Indian pharmaceutical firm Ipca Laboratories Ltd IPCA.NS said on Monday it has agreed to buy a 33.38% stake in Unichem Laboratories Ltd UNLB.NS for up to 10.34 billion ...

MUMBAI, Jan 23 (Reuters) - The U.S. Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Ipca Laboratories Ltd's plant at Ratlam in the central Madhya Pradesh state due ...

Broker's Call recommends buying Ipca Laboratories with a target price of ₹1,710, citing strong financial performance and ...

Ipca remains on a robust growth path in domestic formulation segment, as the company not only delivered healthy double-digit YoY growth but also outperformed the industry.

IPCA Laboratories, one of the biggest pharmaceutical companies in India, has been hit by a cybercrime and extortion group that claims to have stolen 500 gigabytes of data from its systems.